AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03061032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir 24W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
Study NCT03061032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir plus Ribavirin 24W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
Study NCT06418607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral
Study NCT06418607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Hard Capsule-Route of administration:Oral
Study NCT02428842 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor biopsies
Description: Tumor biopsies will be performed before and after treatment.
Study NCT02428842 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be performed before and after treatment.
Study NCT01238016 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: experimental
Study NCT04247633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
Study NCT01732302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
Study NCT01411436 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients who have received Nexavar for unresectable HCC
Study NCT01841242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alcoholic povidone iodine
Study NCT01841242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcoholic chlorhexidine
Study NCT02135211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Study NCT02961621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Training for 9-1-1 Telecommunicators
Study NCT01590550 — intervention group
Intervention type: PROCEDURE
Intervention: Use of citrate based dialysate
Description: Use of heparin free citrate based dialysate
Study NCT03803059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinPen Precision
Description: Surgical instrument motors and accessories/attachments/Hydrogel
Study NCT02511730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFDM Plus DBT
Description: FujiFilm Aspire Cristalle System
Study NCT02511730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFDM
Description: FujiFilm Aspire Cristalle System
Study NCT02509806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 500 mg qd p.o.
Study NCT02350972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cytokines
Description: Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
Study NCT01731379 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
Study NCT03008850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.
Study NCT03008850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.
Study NCT00606203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
Study NCT00606203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00385502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
Description: nail lacquer applied daily for 48 weeks
Study NCT06262958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Adolescent psychiatric outpatient will be offered an e-form of ASSIST alcohol and substance use mini-intervention. Results will be compared to those who received TAU.
Study NCT06262958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Psychotherapy and/or psychotropic drug treatment
Study NCT06262958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Psychotherapy and/or psychotropic drug treatment
Study NCT03957772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extrafascial injection
Description: Extrafascial injection of local anaesthetic under ultrasound guidance
Study NCT03957772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrafascial injection
Description: Intrafascial injection of local anaesthetic under ultrasound guidance
Study NCT02258451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
Study NCT02258451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Up to 6 cycles of saline injection
Study NCT02258451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: One 25 mg tablet once daily after a meal.
Study NCT02258451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: One 25 mg tablet once daily after a meal.
Study NCT02258451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice.
Study NCT02258451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice.
Study NCT03402529 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast Enhanced Spectral Mammography
Description: Pilot study
Study NCT02971462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ischemic conditioning
Description: In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
Study NCT02860364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest
Description: During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
Study NCT02860364 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic circulatory arrest
Description: During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
Study NCT02864368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle
Study NCT02864368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21-day TMZ
Description: Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
Study NCT02864368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component A
Description: 500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered
Study NCT02864368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria booster
Description: At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
Study NCT02864368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Pre-Conditioning
Description: All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
Study NCT02864368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-CMV: Component B
Description: 500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered
Study NCT02707783 — intervention group
Intervention type: DEVICE
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Study NCT04124913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG Oral Tablet
Description: Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
Study NCT04124913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Vaginal Gel [Crinone]
Description: Vaginal progesterone gel 90 mg once a day for luteal phase support
Study NCT02652338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNC-01
Description: twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
Study NCT02652338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
Study NCT04066491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
Study NCT04066491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
Study NCT04066491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
Study NCT04066491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
Study NCT04066491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
Study NCT04066491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
Study NCT03650816 — intervention group
Intervention type: OTHER
Intervention: Doppler ultrasonography
Description: Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
Study NCT03650816 — intervention group
Intervention type: OTHER
Intervention: Biospecimen collection
Description: Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
Study NCT02727985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist weaning schedule
Description: individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
Study NCT03641963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vittamed 205 Non-invasive intracranial pressure (ICP) meter
Description: Non-Invasive intracranial pressure measurement
Study NCT01403818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT01403818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide calcium hydrate
Description: oral
Study NCT04186494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Description: GLP-1 analogue treatment in combination with advice on diet and physical exercise
Study NCT04186494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure treatment
Description: Gold standard treatment for obstructive sleep apnea
Study NCT04186494 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Liraglutide and CPAP
Description: Combination of both treatments
Study NCT01803321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilonacept (IL-1 Trap)
Study NCT01803321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT05146921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-strain probiotic
Description: The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup
Study NCT05146921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo similar in appearance and taste to the active intervention but with no active bacteria
Study NCT03459911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar 100mg Tablet
Description: Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)
Study NCT03459911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100mg
Description: Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
Study NCT00400881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automatic tube compensation
Description: new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
Study NCT02838966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle IMPACT Advanced Recovery
Study NCT02838966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle Boost High Protein Drink
Study NCT01034007 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tissue Engineered Vascular Grafts
Description: Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
Study NCT02256514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daily oral dose of hepcortespenlisimut-L
Description: Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
Study NCT03829657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD (Daily)
Study NCT03829657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, QD
Study NCT02589444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Dose Vitamin D3
Description: 50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stool Sample
Description: Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool Sample
Description: Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool Sample
Description: Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sputum Sample
Description: Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up.
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum Sample
Description: Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up.
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sputum Sample
Description: Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up.
Study NCT02589444 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
Study NCT02589444 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Blood draw
Description: Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
Study NCT02589444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
Study NCT02589444 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
Study NCT01255644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900 mg every 24 hours per os, day 1 through 90